Griffin M Weber, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 16 | 2023 | 4230 | 1.390 |
Why?
|
| Information Storage and Retrieval | 8 | 2019 | 827 | 1.170 |
Why?
|
| Computer Communication Networks | 3 | 2014 | 286 | 0.900 |
Why?
|
| Cell Biology | 2 | 2021 | 95 | 0.840 |
Why?
|
| Medical Record Linkage | 3 | 2021 | 286 | 0.790 |
Why?
|
| Atlases as Topic | 1 | 2021 | 235 | 0.790 |
Why?
|
| Cells | 1 | 2021 | 173 | 0.780 |
Why?
|
| Biomedical Research | 9 | 2017 | 3273 | 0.570 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2018 | 740 | 0.540 |
Why?
|
| Search Engine | 2 | 2015 | 135 | 0.530 |
Why?
|
| Software | 6 | 2022 | 4350 | 0.490 |
Why?
|
| Privacy | 4 | 2022 | 211 | 0.460 |
Why?
|
| Cell Lineage | 2 | 2021 | 2611 | 0.450 |
Why?
|
| Models, Organizational | 1 | 2015 | 587 | 0.420 |
Why?
|
| Algorithms | 11 | 2022 | 13669 | 0.410 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2154 | 0.410 |
Why?
|
| Hospital Shared Services | 1 | 2009 | 15 | 0.380 |
Why?
|
| Data Collection | 2 | 2021 | 3293 | 0.370 |
Why?
|
| Internet | 7 | 2015 | 3078 | 0.350 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2013 | 1208 | 0.350 |
Why?
|
| Intracranial Hemorrhages | 4 | 2022 | 812 | 0.350 |
Why?
|
| Pandemics | 3 | 2022 | 7213 | 0.330 |
Why?
|
| Information Dissemination | 4 | 2021 | 1098 | 0.310 |
Why?
|
| Hospital Information Systems | 1 | 2009 | 364 | 0.310 |
Why?
|
| Inpatients | 1 | 2018 | 2242 | 0.310 |
Why?
|
| Genetic Markers | 2 | 2004 | 2690 | 0.300 |
Why?
|
| Artificial Intelligence | 3 | 2018 | 1729 | 0.280 |
Why?
|
| Research Design | 1 | 2020 | 5876 | 0.260 |
Why?
|
| Research Personnel | 3 | 2021 | 517 | 0.250 |
Why?
|
| User-Computer Interface | 3 | 2012 | 1433 | 0.250 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 1562 | 0.250 |
Why?
|
| Enoxaparin | 2 | 2017 | 361 | 0.250 |
Why?
|
| Evidence-Based Medicine | 2 | 2013 | 3701 | 0.240 |
Why?
|
| Faculty, Medical | 3 | 2017 | 1162 | 0.240 |
Why?
|
| Career Mobility | 2 | 2016 | 264 | 0.240 |
Why?
|
| Confidentiality | 3 | 2019 | 599 | 0.230 |
Why?
|
| Genetics, Microbial | 1 | 2002 | 64 | 0.220 |
Why?
|
| Health Services Research | 1 | 2009 | 1837 | 0.210 |
Why?
|
| Information Systems | 2 | 2014 | 390 | 0.210 |
Why?
|
| Sequence Alignment | 1 | 2005 | 2287 | 0.200 |
Why?
|
| Decision Making | 2 | 2013 | 3828 | 0.200 |
Why?
|
| Venous Thromboembolism | 3 | 2018 | 1573 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2004 | 3994 | 0.190 |
Why?
|
| Hospitalization | 6 | 2022 | 9718 | 0.190 |
Why?
|
| Computer Graphics | 1 | 2021 | 358 | 0.190 |
Why?
|
| Anticoagulants | 4 | 2022 | 4368 | 0.180 |
Why?
|
| Boston | 5 | 2018 | 9400 | 0.170 |
Why?
|
| Humans | 55 | 2023 | 715124 | 0.170 |
Why?
|
| Phylogeny | 1 | 2005 | 2799 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2021 | 761 | 0.160 |
Why?
|
| Chromosome Mapping | 2 | 2005 | 4824 | 0.160 |
Why?
|
| Computer Security | 2 | 2021 | 260 | 0.160 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 4849 | 0.160 |
Why?
|
| Brain Neoplasms | 4 | 2022 | 8804 | 0.160 |
Why?
|
| Insurance Claim Reporting | 1 | 2017 | 168 | 0.160 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2018 | 328 | 0.150 |
Why?
|
| Academic Medical Centers | 4 | 2017 | 2787 | 0.150 |
Why?
|
| Evolution, Molecular | 1 | 2005 | 1963 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 2 | 2005 | 4910 | 0.150 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4311 | 0.150 |
Why?
|
| Salicylates | 1 | 2016 | 129 | 0.150 |
Why?
|
| Disease | 1 | 2021 | 703 | 0.140 |
Why?
|
| Physicians | 1 | 2013 | 4341 | 0.140 |
Why?
|
| Heart Failure | 1 | 2018 | 10123 | 0.130 |
Why?
|
| Medical Subject Headings | 1 | 2013 | 16 | 0.120 |
Why?
|
| Computational Biology | 3 | 2020 | 3557 | 0.120 |
Why?
|
| Intelligence | 2 | 2022 | 900 | 0.120 |
Why?
|
| Programming Languages | 1 | 2014 | 153 | 0.120 |
Why?
|
| Financing, Government | 1 | 2017 | 480 | 0.120 |
Why?
|
| PubMed | 1 | 2013 | 119 | 0.120 |
Why?
|
| Research Support as Topic | 1 | 2017 | 720 | 0.110 |
Why?
|
| Publishing | 2 | 2021 | 800 | 0.110 |
Why?
|
| Information Services | 1 | 2014 | 244 | 0.110 |
Why?
|
| Retrospective Studies | 12 | 2023 | 72255 | 0.110 |
Why?
|
| Information Seeking Behavior | 1 | 2014 | 129 | 0.110 |
Why?
|
| Health Care Surveys | 2 | 2018 | 2509 | 0.110 |
Why?
|
| United States | 13 | 2021 | 67665 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2021 | 791 | 0.110 |
Why?
|
| Natural Language Processing | 1 | 2020 | 956 | 0.110 |
Why?
|
| Databases, Factual | 5 | 2021 | 7836 | 0.110 |
Why?
|
| Databases, Genetic | 3 | 2009 | 1799 | 0.100 |
Why?
|
| Science | 1 | 2013 | 245 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 12477 | 0.100 |
Why?
|
| Universities | 2 | 2014 | 885 | 0.090 |
Why?
|
| Fractures, Compression | 1 | 2011 | 131 | 0.090 |
Why?
|
| Bibliometrics | 1 | 2013 | 334 | 0.090 |
Why?
|
| Hospital Administration | 1 | 2013 | 330 | 0.090 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 990 | 0.090 |
Why?
|
| Public Policy | 1 | 2013 | 549 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3695 | 0.090 |
Why?
|
| Suicide | 1 | 2020 | 1567 | 0.090 |
Why?
|
| Hospitals | 1 | 2021 | 3331 | 0.090 |
Why?
|
| Databases, Nucleic Acid | 1 | 2009 | 213 | 0.090 |
Why?
|
| Database Management Systems | 1 | 2010 | 287 | 0.090 |
Why?
|
| Medical Informatics | 2 | 2014 | 736 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2004 | 9521 | 0.090 |
Why?
|
| Genome, Human | 1 | 2002 | 4471 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 19499 | 0.080 |
Why?
|
| Systems Integration | 1 | 2010 | 448 | 0.080 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2012 | 601 | 0.080 |
Why?
|
| Logistic Models | 1 | 2002 | 13594 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2266 | 0.070 |
Why?
|
| Genomics | 1 | 2021 | 5333 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2009 | 575 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1622 | 0.070 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 1374 | 0.070 |
Why?
|
| Middle Aged | 13 | 2023 | 214871 | 0.070 |
Why?
|
| Expressed Sequence Tags | 2 | 2004 | 261 | 0.070 |
Why?
|
| Overweight | 1 | 2016 | 2237 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2008 | 491 | 0.070 |
Why?
|
| Research | 1 | 2014 | 2018 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 485 | 0.070 |
Why?
|
| Climacteric | 1 | 2004 | 57 | 0.070 |
Why?
|
| Stochastic Processes | 1 | 2005 | 332 | 0.070 |
Why?
|
| Models, Theoretical | 3 | 2013 | 3563 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 1407 | 0.070 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2005 | 1126 | 0.060 |
Why?
|
| Spinal Fractures | 1 | 2011 | 688 | 0.060 |
Why?
|
| ROC Curve | 2 | 2022 | 3526 | 0.060 |
Why?
|
| Phenotype | 1 | 2021 | 16371 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 4924 | 0.060 |
Why?
|
| Diagnosis | 1 | 2004 | 155 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2011 | 833 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1458 | 0.060 |
Why?
|
| Logical Observation Identifiers Names and Codes | 1 | 2022 | 16 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 16011 | 0.060 |
Why?
|
| Gene Library | 2 | 2004 | 1093 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2018 | 3748 | 0.060 |
Why?
|
| Glioma | 1 | 2017 | 3295 | 0.060 |
Why?
|
| Female | 16 | 2021 | 377334 | 0.060 |
Why?
|
| Male | 13 | 2021 | 351081 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2005 | 1247 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2020 | 2033 | 0.050 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 1164 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 23511 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 12567 | 0.050 |
Why?
|
| Neoplasms | 2 | 2015 | 20515 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2020 | 6423 | 0.050 |
Why?
|
| Ethics Committees, Research | 1 | 2021 | 162 | 0.050 |
Why?
|
| Subtraction Technique | 1 | 2003 | 546 | 0.050 |
Why?
|
| Aged | 7 | 2023 | 162674 | 0.050 |
Why?
|
| Communication | 1 | 2013 | 3498 | 0.050 |
Why?
|
| Adult | 8 | 2023 | 212129 | 0.050 |
Why?
|
| Diabetic Retinopathy | 1 | 2008 | 1204 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 3320 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 775 | 0.040 |
Why?
|
| Obesity | 2 | 2023 | 12192 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2011 | 8042 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2004 | 740 | 0.040 |
Why?
|
| Viruses | 1 | 2002 | 357 | 0.040 |
Why?
|
| Gene Expression | 2 | 2002 | 8010 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2002 | 672 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 2021 | 324 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 2075 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2012 | 9022 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2003 | 1254 | 0.040 |
Why?
|
| Inflammation | 1 | 2016 | 10082 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 1777 | 0.040 |
Why?
|
| Registries | 1 | 2012 | 8090 | 0.040 |
Why?
|
| Government Regulation | 1 | 2021 | 543 | 0.040 |
Why?
|
| Genome | 1 | 2004 | 1750 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 2769 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2022 | 1017 | 0.040 |
Why?
|
| Prognosis | 4 | 2021 | 29168 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2005 | 3513 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 14877 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 18734 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2002 | 2292 | 0.030 |
Why?
|
| San Francisco | 1 | 2014 | 157 | 0.030 |
Why?
|
| Base Sequence | 1 | 2005 | 13315 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 13268 | 0.030 |
Why?
|
| Organizations | 1 | 2014 | 164 | 0.030 |
Why?
|
| Awards and Prizes | 1 | 2017 | 346 | 0.030 |
Why?
|
| Retina | 1 | 2004 | 2642 | 0.030 |
Why?
|
| Vocabulary, Controlled | 1 | 2014 | 192 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 3803 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2022 | 10531 | 0.030 |
Why?
|
| Software Design | 1 | 2012 | 181 | 0.030 |
Why?
|
| Sex Ratio | 1 | 2012 | 103 | 0.030 |
Why?
|
| Efficiency | 1 | 2015 | 491 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2023 | 39804 | 0.030 |
Why?
|
| Carcinoma | 1 | 2002 | 2325 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2005 | 5028 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 3963 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2017 | 882 | 0.020 |
Why?
|
| Mammography | 1 | 2002 | 2475 | 0.020 |
Why?
|
| Demography | 1 | 2015 | 1621 | 0.020 |
Why?
|
| Online Systems | 1 | 2011 | 195 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 5415 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2004 | 13292 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 3004 | 0.020 |
Why?
|
| Incidence | 2 | 2018 | 20596 | 0.020 |
Why?
|
| Educational Status | 1 | 2016 | 2332 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2015 | 1006 | 0.020 |
Why?
|
| Young Adult | 3 | 2023 | 56155 | 0.020 |
Why?
|
| Databases, Protein | 1 | 2009 | 375 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 12404 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 58505 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2021 | 24645 | 0.020 |
Why?
|
| Neurology | 1 | 2015 | 746 | 0.020 |
Why?
|
| Adolescent | 3 | 2023 | 84999 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2020 | 9968 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 625 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2011 | 714 | 0.020 |
Why?
|
| Risk Factors | 3 | 2018 | 70704 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6779 | 0.020 |
Why?
|
| Systems Biology | 1 | 2009 | 492 | 0.020 |
Why?
|
| Infant | 2 | 2021 | 34497 | 0.020 |
Why?
|
| Anesthesiology | 1 | 2015 | 1043 | 0.020 |
Why?
|
| Survival Rate | 2 | 2015 | 13255 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2002 | 20059 | 0.020 |
Why?
|
| Macular Edema | 1 | 2008 | 335 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2021 | 41181 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 344 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 34394 | 0.020 |
Why?
|
| Child | 3 | 2021 | 74146 | 0.020 |
Why?
|
| Time Factors | 3 | 2018 | 41081 | 0.020 |
Why?
|
| General Surgery | 1 | 2015 | 1645 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 6371 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39285 | 0.020 |
Why?
|
| Quality of Life | 1 | 2004 | 11691 | 0.020 |
Why?
|
| Psychiatry | 1 | 2015 | 1615 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10651 | 0.010 |
Why?
|
| Medical Records | 1 | 2008 | 1420 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2016 | 11900 | 0.010 |
Why?
|
| Radiology | 1 | 2015 | 1936 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3130 | 0.010 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 1120 | 0.010 |
Why?
|
| Mathematics | 1 | 2002 | 745 | 0.010 |
Why?
|
| North America | 1 | 2004 | 1196 | 0.010 |
Why?
|
| Markov Chains | 1 | 2004 | 985 | 0.010 |
Why?
|
| Neoplasm Metastasis | 2 | 2002 | 5098 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2004 | 836 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2008 | 1404 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11192 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 1988 | 0.010 |
Why?
|
| Pediatrics | 1 | 2015 | 3553 | 0.010 |
Why?
|
| Animals | 3 | 2009 | 170726 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 425 | 0.010 |
Why?
|
| Interneurons | 1 | 2004 | 576 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 2095 | 0.010 |
Why?
|
| Visual Acuity | 1 | 2008 | 2503 | 0.010 |
Why?
|
| Neuroglia | 1 | 2004 | 920 | 0.010 |
Why?
|
| Mitosis | 1 | 2004 | 1255 | 0.010 |
Why?
|
| Disease Progression | 2 | 2008 | 13302 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2004 | 1610 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 2272 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2004 | 1122 | 0.010 |
Why?
|
| Comorbidity | 1 | 2012 | 10423 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2746 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 21790 | 0.010 |
Why?
|
| Prevalence | 1 | 2012 | 14869 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2002 | 1102 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 3702 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 2038 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 3364 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6290 | 0.010 |
Why?
|
| Mortality | 1 | 2004 | 2794 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 9895 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 13573 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 62186 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 9772 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2016 | 51181 | 0.010 |
Why?
|
| Stem Cells | 1 | 2004 | 3589 | 0.010 |
Why?
|
| African Americans | 1 | 2004 | 5065 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 4028 | 0.000 |
Why?
|
| Mass Screening | 1 | 2002 | 5204 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 12425 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 10980 | 0.000 |
Why?
|
| Smoking | 1 | 2001 | 8932 | 0.000 |
Why?
|
| Mice | 1 | 2004 | 80995 | 0.000 |
Why?
|